A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
Multiple myeloma (MM) is characterized by the over-production of monoclonal plasma cells that eventually become malignant in the bone marrow. MM remains as an incurable cancer, but it can be treated through chemotherapy. Nonetheless, research on novel therapies for effective treatment of MM is ongo...
Saved in:
Main Authors: | Sze-Ting Bong, Lydia Ngiik-Shiew Law, Jodi Woan-Fei Law |
---|---|
Format: | Article |
Language: | English |
Published: |
HH Publisher
2019-05-01
|
Series: | Progress in Microbes and Molecular Biology |
Online Access: | https://journals.hh-publisher.com/index.php/pmmb/article/view/60 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
by: Li Zhang, et al.
Published: (2023-01-01) -
Experimental and Density Functional Theory Characteristics of Ibrutinib, a Bruton’s Kinase Inhibitor Approved for Leukemia Treatment
by: Ali I. Ismail
Published: (2021-01-01) -
Role of Bruton's Tyrosine Kinase in B Cell Development
by: Alex Maas, et al.
Published: (2001-01-01) -
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
by: Benjamin M. Heyman, et al.
Published: (2025-02-01) -
Insights into quorum sensing (QS): QS-regulated biofilm and inhibitors
by: Wen-Si Tan, et al.
Published: (2020-11-01)